Evaxion, a leader in AI-based biotechnology, will attend this year’s ESMO Immuno-Oncology Congress and present a customizable cancer vaccine customizable cancer vaccine powered by in-house AI technology. The system uses AI to examine a patient’s data, focusing on a single target: VRE tumor antigens that show a tendency to be shared by multiple patients. The goal is actually quite simple: AI searches for antigens, which trigger the body’s production of immunity, which are shared by several cancer patients, and reconfigures them into a vaccine suitable for each type of cancer. cancer and, in some cases, to each patient.
Evaxion is very discreet about the elements that go into the development of its proprietary AI systems. The company says, however, that it has developed four different models, which are designed to work together in this product. The EDEN model is designed to look for antigens that will trigger the type of immune response capable of banishing a bacterial infection. OBSERV is designed to complement a patient’s existing antigens, with a focus on VREs, remnants of ancient immunities written into the human genome over millennia. PIONEER, on the other hand, is designed to search for patient-specific antigens that can be activated by immunotherapy. Finally, RAVEN is a model used to verify the effectiveness of possible vaccine candidates. Together, these models should, in theory, be able to identify the best possible immune treatment for a given cancer patient.
Evaxion calls this system AI-Immunology and has relied heavily on it since the company’s beginnings. Since its IPO and the arrival of a large number of investors in 2021, Evaxion has managed to secure major deals with big names. One of the largest and most recent is a deal with US pharmaceutical company Merck & Co, which is based on milestones and could see Evaxion receive more than $1 billion, if all goes well. The company’s commercial portfolio currently includes vaccines for staph and gonorrhea, to name a few.
Health
